Biogen (BIIB) Equity Income (2012 - 2022)

Biogen's Equity Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q3 2022.

• In Q3 2022, Equity Income fell 92.44% year-over-year to $3.4 million; the TTM figure through Jun 2023 stood at $3.4 million (down 97.42% YoY), while the FY2022 annual figure was $2.6 million, down 92.55% from the prior year.
• Equity Income was $3.4 million for Q3 2022 at Biogen, down from $45.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $45.0 million in Q2 2021 to a low of -$28.7 million in Q1 2019.
• Historically, Equity Income has averaged $15.7 million across 4 years, with a median of $25.9 million in 2019.
• The sharpest annual moves came in 2020 and 2022: Equity Income soared 307.36% in 2020, then slumped 92.44% in 2022.
• A 4-year view of Equity Income shows it stood at $33.8 million in 2019, then tumbled by 46.75% to $18.0 million in 2020, then jumped by 150.0% to $45.0 million in 2021, then plunged by 92.44% to $3.4 million in 2022.
• The last three Equity Income figures came in at $3.4 million (Q3 2022), $45.0 million (Q2 2022), and -$3.3 million (Q1 2022), per Business Quant data.